http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2465746-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-224 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-224 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 |
| filingDate | 1980-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7fb8cf2e2fd3ce5931f199f469653e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec805a449a29b7abad65f3f19624ff1d |
| publicationDate | 1981-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2465746-A1 |
| titleOfInvention | 1-EPI-2-DESOXYFORTIMICIN B AND ITS DERIVATIVES USEFUL AS ANTIBIOTICS |
| abstract | THE NEW COMPOUNDS OF THE INVENTION MEET THE GENERAL FORMULA: (CF DRAWING IN BOPI) IN WHICH R IS A HYDROGEN ATOM OR A LOWER ALKYL GROUP AND R IS CHOSEN FROM THE LOWER ALKYL, LOWER AMINOALKYL, LOWER NAMINOALKYL, LOWER DIAMINO GROUP - (LOWER ALKYL) -AMINOALKYL LOWER, N, N-DI (ALKYL LOWER) -AMINOALKYL LOWER, HYDROXYALKYL LOWER, AMINOHYDROXYALKYL LOWER, N- (ALKYLINERXYRALKYL-INFERIE-N- (ALKYLINERXYRALKYL-INFERIE, N- (ALKYLINERXYRALKYL-INFERIE-N- (ALKYLINERXYRALKYL), N- (N- (ALKYLINERXYRALKYL-INFERAL, N- (ALKYLINERXYRALKYL-INFERAL) , ACYL, AMINOACYL, DIAMINOACYL, HYDROXYACYL, AMINOACYL HYDROXY-SUBSTITUTE, DIAMINOACYL HYDROXY-SUBSTITUTE, N- (LOWER ALKYL) -AMINOACYL, N, N-DIINYLE (ALKYLACYL-INFERIE- N-DIAMINOACYL-INFERIE- N, N-DIINYUR (ALKYLACYL), N, N-DIINYURO (ALKYLAMYL) SUBSTITUTE OR N, N-DI (LOWER ALKYL) -AMINOACYL HYDROXY-SUBSTITUTE, WITH THE CONDITION THAT R CANNOT BE A GLYCYL, FORMYLGLYCYL OR HYDANTOYL GROUP. APPLICATIONS AS ANTIBIOTICS, IN INTRAVENOUS, INTRAMUSCULAR, INTRAPERITONEAL OR SUCUTANEOUS FORMS OF ADMINISTRATION AT DAILY DOSES OF 10 TO 100 MGKG OF BODY WEIGHT, PREFERABLY OF ABOUT 15 TO 30 MGKG, PREFERABLY TO 4 PREFERENCES PER DAY . |
| priorityDate | 1979-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.